Authors
Latest:
Ashani Weeraratna on Aging and MelanomaAshani Weeraratna, PhD, associate professor, Tumor Microenvironment and Metastasis Program, member, The Wistar Institute Melanoma Research Center, discusses a study examining the effects of aging on Wnt/ß-catenin signaling in melanoma.
Latest:
Dr. Chanan-Khan on Ibrutinib as Backbone of Treatment for CLLAsher A. Chanan-Khan, MD, chair, Hematology/Oncology, Mayo Clinic in Florida, discusses ibrutinib as a backbone of treatment for patients with chronic lymphocytic leukemia (CLL).
Latest:
Dr. Kamat on the Process of Meeting BCG Needs in Bladder CancerAshish M. Kamat, MD, discusses the process of meeting the needs for TICE Bacillus Calmette–Guérin in the treatment of patients with bladder cancer.
Latest:
Dr Saxena on Shifts in Treatment With Targeted and Immune Therapies in NSCLCAshish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.
Latest:
Primary Radiation Therapy for Myeloid Sarcoma of the Porta HepatisTreating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.
Latest:
Dr. Weiner on Radiotherapy Trials in NSCLCAshley A. Weiner, MD, PhD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses clinical trials that have investigated the use of radiotherapy in patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Rosko on Disparities Within Clinical Trials in Multiple MyelomaAshley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.
Latest:
Innovation in EHR Technology Drives Quality Oncology CareThe mantra in oncology over the last several years has revolved around how practices should deal with the myriad of challenges they face: new guidelines and regulations, lower reimbursement and a shift toward value-based patient care.
Latest:
Dr. Amin on CheckMate-214 Trial in RCCAsim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses the rationale for the pivotal CheckMate-214 trial in advanced renal cell carcinoma.
Latest:
It's Time to Integrate Complementary Medicine Discussions Into Oncology CareThe goal of increasing communications with the patient about all available and useful therapies contributes to better care of individuals and allows for continued education from oncology providers on potential risks and benefits of such therapies.
Latest:
Dr. Sacco on Ongoing Trials for Chemoradiation in Head and Neck CancerAssuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses ongoing trials investigating chemoradiation for patients with head and neck cancer.
Latest:
Dr. Hussein on the Evolution of Treatment in HCCAtif Hussein, MD, discusses the evolution treatment in hepatocellular carcinoma.
Latest:
Dr. Choudhury on The Need for Biomarkers to Predict Benefit With PARP Inhibitors in mCRPCAtish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.
Latest:
ASH 2010: CPX-351 Improves Response in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaThe novel first-in-class agent CPX-351 liposome injection improved response rates and eventfree survival in elderly patients with newly diagnosed acute myeloid leukemia.
Latest:
Xevinapant Plus Standard Chemoradiotherapy Demonstrates Sustained Benefit in Locally Advanced HNSCCThe addition of xevinapant to standard-of-care chemoradiotherapy elicited continued 5-year overall survival and 3-year duration of response benefits in patients with unresected head and neck locally advanced squamous cell carcinoma.
Latest:
Dr. Villanueva on Eliminating Tumor Heterogeneity in Patients With HCCAugusto Villanueva, MD, an assistant professor of the Division of Liver Diseases at the Tisch Cancer Institute of Icahn School of Medicine at Mount Sinai, discusses mutations and gene signatures for patients with hepatocellular carcinoma, a topic he presented at the 2020 Gastrointestinal Cancers Symposium.
Latest:
Dr. Villanueva on Challenges For Liquid Biopsies in HCCAugusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses remaining challenges with liquid biopsies in hepatocellular carcinoma.
Latest:
Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.
Latest:
Researchers Investigate Increased Incidence of Thyroid Cancer in CaliforniaTo investigate the possibility of environmental impacts as a predisposition for thyroid cancer, researchers sought to identify counties in California with possible geographic clustering of advanced thyroid cancer cases.
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume DelineationThe ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.
Latest:
Dr. Grothey on the Potential Role of ctDNA as a Marker for Rechallenging Treatment in CRCAxel Grothey, MD, discusses the potential utility of circulating tumor DNA as a marker for rechallenging patients with treatment in colorectal cancer.
Latest:
Open Questions and Future Directions in mCRCExperts in CRC discuss questions and management of mCRC.
